A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019
暂无分享,去创建一个
P. López-Jaramillo | C. Vlachopoulos | H. Milionis | E. Giamarellos‐Bourboulis | P. Katsaounou | N. Sweitzer | J. Chirinos | Jordana B. Cohen | G. Poulakou | R. Moghnieh | Z. Alexiou | R. Carrasco | A. Bizri | J. Andrade-Villanueva | C. Cure-Cure | M. Putt | M. Pérez-Mayorga | C. Gutierrez | G. Sánchez | J. Hernandez | I. Dimitroulis | S. Sympardi | Renzo Valdivia-Vega | T. Sharkoski | L. González-Hernández | J. Chittams | M. Giraldo | M. Pariona | Gonzalo Davila-del-Carpio | Oday Salman | Nelson R Rosado-Santander | Rapti Angeliki | María Cruz Saldarriaga | Carola Medina | Juan E Rodriguez-Mori | Edgar Gomez-Laiton | Rosa Pereyra | Jorge Ravelo Hernández | H. Arbañil | J. Accini-Mendoza | Mirko Villavicencio-Carranza | Ricardo J Ayala-García | Carlos A Castro-Callirgos | Willy Lecca Danos | K. Greene | Bianca Pourmussa | Candy Greczylo | Tiffany Sharkoski
[1] B. Haagmans,et al. SARS-CoV-2 pathogenesis , 2022, Nature Reviews Microbiology.
[2] Leiliang Zhang,et al. Palmitoylation of SARS‐CoV‐2 S protein is critical for S‐mediated syncytia formation and virus entry , 2021, Journal of medical virology.
[3] Zhuanchang Wu,et al. Palmitoylation of SARS-CoV-2 S protein is essential for viral infectivity , 2021, Signal Transduction and Targeted Therapy.
[4] G. Ippolito,et al. Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis , 2021, Cell Death & Disease.
[5] I. Adcock,et al. COVID-19: Molecular and Cellular Response , 2021, Frontiers in Cellular and Infection Microbiology.
[6] Shijian Zhang,et al. Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects , 2020, Journal of Virology.
[7] Sharon J Peacock,et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[8] Fang Lei,et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.
[9] B. Boehm,et al. Endocrine and metabolic link to coronavirus infection , 2020, Nature Reviews Endocrinology.
[10] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[11] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[12] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[13] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[14] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[15] J. Chan,et al. Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication , 2019, Viruses.
[16] M. Fay,et al. Confidence intervals of the Mann‐Whitney parameter that are compatible with the Wilcoxon‐Mann‐Whitney test , 2018, Statistics in medicine.
[17] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[18] K. Anstrom,et al. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. , 2017, Journal of the American College of Cardiology.
[19] K. Anstrom,et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.
[20] A. Gorbalenya,et al. Modulation of the Host Lipid Landscape to Promote RNA Virus Replication: The Picornavirus Encephalomyocarditis Virus Converges on the Pathway Used by Hepatitis C Virus , 2015, PLoS pathogens.
[21] U. Ladabaum,et al. Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010. , 2014, The American journal of medicine.
[22] D. Hilleman,et al. A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations , 2013, Cardiology research.
[23] G. Felker,et al. A global rank end point for clinical trials in acute heart failure. , 2010, Circulation. Heart failure.
[24] I. Hozo,et al. Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.
[25] S. Julious. Sample sizes for clinical trials with Normal data , 2004, Statistics in medicine.
[26] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[27] P. Elteren. On the combination of independent two-sample tests of wilcoxon : Corrected version , 1959 .